Mucolytics and Expectorants
Key Points
- Mucolytics and expectorants are two distinct classes of drugs used to clear respiratory secretions, though they work by different mechanisms.
- Expectorants (e.g., guaifenesin) increase respiratory tract fluid production to liquefy mucus and make it easier to expel; they should only be used for productive coughs.
- Mucolytics (e.g., acetylcysteine, dornase alfa) directly break the protein bonds within mucus, reducing its viscosity and stickiness — used for thick, tenacious secretions.
- Acetylcysteine (Mucomyst) is the primary mucolytic in clinical use; it is also the antidote for acetaminophen toxicity when administered orally or intravenously.
- Dornase alfa (Pulmozyme) is used specifically in cystic fibrosis to thin mucus and reduce lung infections.
- Dornase alfa handling requires cold-chain/light protection practices and should not be mixed with other medications in the nebulizer.
Mechanism of Action
Expectorants
Expectorants lubricate the airways and stimulate the cough reflex by increasing the production of respiratory tract fluids, which decreases mucus viscosity and makes it easier to expel. They do not suppress the cough and are appropriate only when clearing productive secretions is the goal.
Prototype: Guaifenesin
- Available over the counter as a stand-alone or combination cold/flu preparation
- Increases respiratory tract fluid to liquefy mucus
- Dose: 200 mg orally every 4 hours; extended-release 600–1200 mg every 12 hours (maximum 2400 mg/day)
- Adverse effects: headache, dizziness, nausea, vomiting, urticaria
- Contraindicated in hypersensitivity; extended-release preparations contraindicated in children under age 12
Mucolytics
Mucolytics directly break down the molecular structure of mucus by cleaving its disulfide protein bonds, reducing thickness and stickiness without relying on increased secretion or cough reflex stimulation.
| Drug | Route | Primary Indication |
|---|---|---|
| Acetylcysteine (Mucomyst) | Inhalation, IT instillation, oral, IV | Thick secretions in pneumonia, bronchitis, cystic fibrosis, emphysema; tracheostomy care; bronchoscopy prep; acetaminophen toxicity antidote |
| Dornase alfa (Pulmozyme) | Inhalation | Cystic fibrosis — reduces lung infections by thinning mucus |
Dornase alfa handling and administration considerations:
- Deliver via nebulizer as prescribed; do not mix with other medications in the nebulizer chamber.
- Keep refrigerated and protected from light; maintain foil pouch protection until use.
- Avoid leaving at room temperature longer than 24 hours.
- Discard opened medication units per product policy.
- Monitor for adverse effects such as voice changes, throat discomfort, rash, watery/red eyes, chest symptoms, fever, or decreased lung function.
Acetylcysteine dosing (respiratory):
- Secretion clearance: 1–2 mL of 10–20% solution instilled into trachea as often as every hour
- Bronchoscopy prep: 2–3 administrations of 1–2 mL of 20% solution, or 2–4 mL of 10% solution prior to procedure
- Routine tracheostomy care: 1–2 mL of 10–20% solution by direct instillation every 1–4 hours
Nursing Assessment
NCLEX Focus
Know that mucolytics are for thick, tenacious secretions in high-risk clients (tracheostomy, cystic fibrosis), while expectorants are for productive coughs needing secretion thinning — selecting the wrong class is a common distractor.
- Assess the client’s respiratory status for signs of distress, oxygen saturation, and breath sounds.
- Identify the underlying cause and nature of the cough: productive vs. nonproductive, frequency, volume, and character of sputum.
- Review allergy history, current medication list, and medical history before administration.
- For acetylcysteine: assess pulmonary function and history of asthma — clients with asthma are at increased risk for bronchospasm.
Nursing Interventions
- Administer expectorants only for productive coughs — they are not appropriate for dry, nonproductive coughs.
- Encourage adequate oral fluid intake to augment mucolytic/expectorant effectiveness and help loosen secretions.
- Teach and assist with deep breathing exercises to mobilize secretions.
- Monitor vital signs in clients taking mucolytics: assess for fever and tachycardia (acetylcysteine adverse effects).
- For acetylcysteine inhaled via nebulizer: have suction available; the drug has a sulfur-like odor that may cause nausea.
- Bronchospasm alert: Monitor clients with asthma closely during acetylcysteine administration; have bronchodilator available.
- For dornase alfa in cystic fibrosis: verify storage/light handling and reinforce that the dose is not co-nebulized with other medications unless explicitly ordered.
- Educate the client to:
- Take as prescribed and only for the duration indicated
- Increase fluid intake and deep breathing exercises
- Notify the provider if symptoms persist longer than one week, worsen, or are accompanied by fever, rash, or worsening dyspnea
Acetylcysteine Dual Role
Acetylcysteine used for respiratory secretions (inhaled/instilled) is the same drug used as the antidote for acetaminophen toxicity (oral/IV). The route and dose differ significantly. Always verify the indication and route before administration.
Related Concepts
- bronchial-hygiene-techniques — Airway clearance techniques that complement mucolytic therapy.
- evidence-based-respiratory-care — Evidence-based bundle care incorporating mucolytics in ventilated patients.
- bronchodilators — Companion respiratory medications used in clients with airflow obstruction.
- respiratory-system — Anatomy of the respiratory tract and mucociliary clearance mechanisms.
- pain-management — Acetaminophen toxicity context for acetylcysteine antidote use.
Self-Check
- How do mucolytics differ from expectorants in their mechanism of action, and when is each class most appropriate?
- A client with asthma is receiving inhaled acetylcysteine. What assessment finding should the nurse prioritize, and what should be kept available at the bedside?
- What is the maximum daily dose of guaifenesin, and in which cough type is it contraindicated?